Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website
  • Reminder to Premium Members: To enjoy full site functionality & avoid the bugs currently affecting recommend, delete & other features on our "www" pages, please log in to your premium accounts at https://premium.investorvillage.com If you need assistance, don't hesitate to contact customer support any time. That's a big part of what you pay for, after all!  


ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10010 of 10028  at  6/18/2019 8:51:42 PM  by

jetmanbash


 In response to msg 10008 by  biochemyst
view thread

Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA

Both present PCSK 9 inhibitors are given sq not IV. t


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 207
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10011 Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA Steve_382 7 6/18/2019 9:57:31 PM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...